Chronic lithium and carbamazepine, which are effective against mania in bipolar disorder, decrease the activity of cytosolic phospholipase A 2 (cPLA 2 ) and the turnover rate of arachidonic acid in phospholipids in rat brain. Assuming that stages of bipolar disorder are related to brain arachidonic acid metabolism, we hypothesized that drugs effective in depression would increase cPLA 2 activity. To test this hypothesis, adult male CDF-344 rats were administered fluoxetine (10 mg/kg intraperitoneally (i.p.) or saline (control) (i.p.) chronically for 21 days. Frontal cortex cPLA 2 protein, phosphorylated cPLA 2 , activity and mRNA levels were increased after chronic fluoxetine. Transcription factors (activator protein-1, activator protein-2, glucocorticoid response element, polyoma enhancer element-3 and nuclear factor-kappa B ) that are known to regulate cPLA 2 gene expression were not significantly changed by chronic fluoxetine, but nuclear AU-rich element/poly(U)-binding/degradation factor-1 RNA-stabilizing protein was increased significantly. The results suggest that chronic fluoxetine increases brain cPLA 2 gene expression post-transcriptionally by increasing cPLA 2 mRNA stabilization. Chronic fluoxetine's effect on cPLA 2 expression was opposite to the effect reported with chronic lithium or carbamazepine administration, and may be part of fluoxetine's mode of action.
Introduction
The antidepressant drug fluoxetine (Prozac) is widely used to treat major depression and, in combination with a mood stabilizer, to treat the depressive phase of bipolar disorder. 1, 2 Fluoxetine is a selective serotonin (5-HT) reuptake inhibitor (SSRI) that increases the amount of 5-HT available for signaling in the synaptic cleft. 3, 4 As 5-HT levels are increased before changes in patient's mood, it is likely that neuroplastic changes in signaling are required for fluoxetine's therapeutic effectiveness. 5 Neuroplastic effects that include downregulation of 5-HT 1A autoreceptors and increased synaptic 5-HT content are involved in the onset of antidepressant efficacy. 6, 7 These effects are only seen with chronic but not with acute fluoxetine administration. 6, 8, 9 In this regard, chronic fluoxetine administration upregulates 5-HT 2C receptors in the rat choroid plexus, 10 increases rat brain 5-HT 2A receptor signaling 11 and increases 2,5-dimethoxy-4-iodoamphetamine-induced cFOSÀ gene expression.
Consistent with the above, [
18 F]setoperone binding to 5-HT 2A receptors is increased in fluoxetine-treated depressed patients compared to untreated depressed patients. 13 Despite the many cellular and molecular targets of fluoxetine, its mechanism of action is not agreed upon. Arachidonic acid (20:4n-6 ) is a nutritionally essential polyunsaturated fatty acid predominately found in the stereospecifically numbered-2 (sn-2) position of membrane phospholipids. It can be released by a calcium-dependent arachidonic acid-selective cytosolic phospholipase A 2 (cPLA 2 ), which is found in post-synaptic sites in the brain. 14 In addition to cPLA 2 , secretory and Ca 2 þ -independent phospholipase A 2 (sPLA 2 and iPLA 2 , respectively) can cleave fatty acids at the same sn-2 position as cPLA 2 . However, they differ in their calcium requirement, and phosphorylation and substrate specificities. [15] [16] [17] [18] [19] A portion of the released arachidonic acid will be converted to bioactive eicosanoids via cyclooxygenase-1 or cyclooxygenase-2, lipoxygenase or cytochrome P450 epoxygenase enzymes. 20, 21 The released arachidonic acid and its metabolites can modulate signal transduction, transcriptional regulation, neuronal activity, apoptosis and a number of other processes within the central nervous system. [22] [23] [24] The PLA 2 that releases arachidonic acid from neural membranes can be linked to various G-protein-coupled receptors including 5-HT 2A/2C 25-28 and D 2 -like dopaminergic receptors, 29, 30 as well as to the ionotropic N-methyl-D-aspartate (NMDA) receptor. 31, 32 Acute administration of 5-HT agonists and fluoxetine to unanesthetized rats increases the incorporation coefficient of arachidonic acid from plasma into regions of rat brain that contain 5-HT 2A/2C receptors, as a marker of cPLA 2 activation. 33 When given chronically to rats, drugs that are effective in the manic phase of bipolar disorder (e.g. lithium, valproic acid and carbamazepine) decrease the turnover rate of arachidonic acid in rat brain phospholipids. [34] [35] [36] The ability of lithium and carbamazepine to do so has been ascribed to their decreasing transcription of cPLA 2 . 37, 38 As antidepressant monotherapy of bipolar disorder can induce switching to mania, 2,39,40 chronic administration of fluoxetine to rats might exert the opposite effects on brain arachidonic acid kinetics and cPLA 2 expression, particularly if the symptoms of bipolar disorder are related to the arachidonic acid cascade.
To test this hypothesis, we administered fluoxetine at a therapeutically relevant dose 10 to rats for 21 days, and studied expression of PLA 2 enzymes in the frontal cortex before or after a 3-day saline washout period. We also made measurements 3 h after a single fluoxetine injection. We further examined known cPLA 2 regulating transcription factors and an mRNA-stabilizing protein. 41 We used the frontal cortex for our studies, as functional imaging and post-mortem studies from patients with major depression indicate abnormalities in structure and function within this region. [42] [43] [44] [45] [46] Furthermore, this choice allowed us to compare our results with those on the frontal cortex obtained after chronic administration of lithium and carbamazepine to rats.
47,48

Results
Effect of chronic and acute fluoxetine on cytosolic phospholipase A 2 isoforms in rat frontal cortex Chronic fluoxetine administration (21 days) significantly increased (54%) the frontal cortex cPLA 2 protein level compared to the level in control rats (Figure 1a ) (F ¼ 5.80, df ¼ 2, 19; P ¼ 0.010). This effect was not observed after chronic fluoxetine with a 3-day saline washout or 3 h after acute fluoxetine (Figure 1a and b) . Thus, it represented a chronic neuroplastic effect that became statistically insignificant after 3 days of drug washout. Fluoxetine is not detectable in rat plasma 48 h after 21 days of administration, 49 and brain half-lives of fluoxetine and its active metabolite norfluoxetine are 5 and 15 h, respectively. 50 Effect of chronic fluoxetine on phospho-cytosolic phospholipase A 2 and cytosolic phospholipase A 2 activity in rat frontal cortex Chronic fluoxetine increased (27%) the level of phosphorylated (Ser-505) cPLA 2 protein in rat frontal cortex compared to controls (Figure 1c ) (F ¼ 5.30; df ¼ 2, 20; P ¼ 0.013). However, after the 3-day saline washout, the phosphorylated cPLA 2 level was not significantly different from the control level (Figure 1c ). Cytosolic phospholipase A 2 activity was significantly increased (38%) in the frontal cortex of rats chronically administered fluoxetine (F ¼ 5.77; df ¼ 2, 21 P ¼ 0.010), but not after the 3-day saline washout compared to control activity (Figure 1d ).
Effect of chronic fluoxetine on cytosolic phospholipase A 2 mRNA in rat frontal cortex We further examined the basis for increased cPLA 2 protein levels after chronic fluoxetine, by measuring cPLA 2 mRNA. The frontal cortex cPLA 2 mRNA level was significantly increased (1.7-fold) in rats chronically administered fluoxetine (F ¼ 6.34; df ¼ 2, 15; P ¼ 0.010), but not after a 3-day saline washout compared to the control level ( Figure 1e ).
Effect of chronic fluoxetine on phospholipaseA 2 isoforms in rat frontal cortex Frontal cortex iPLA 2 (F ¼ 1.56; df ¼ 2, 21; P ¼ 0.23) and sPLA 2 (F ¼ 0.70; df ¼ 2, 15; P ¼ 0.47) protein levels were not significantly changed after chronic fluoxetine or chronic fluoxetine with 3-day washout, compared to control levels (Figure 2a and b) .
Effect of chronic fluoxetine on cytosolic phospholipase A 2 -regulating transcription factors An excess amount of cold (100 times) oliogonucleotide blocked the binding of specific cPLA 2 regulating transcription factors (Figure 3a) , indicating the specificity of each transcription factor in rat frontal cortex. We examined whether the increase in cPLA 2 mRNA with the chronic fluoxetine was associated with upregulation of known cPLA 2 regulating transcription factors: activator protein-1(AP-1), activator protein-2 (AP-2), glucocorticoid response element (GRE), nuclear factor-kappa B (NF-kB) and polyoma enhancer element-3 (PEA3). 51 There was no significant change in the binding activity of AP-1, NF-kB, GRE, PEA3 or AP-2 in the frontal cortex of rats chronically administered fluoxetine (Figure 3b -f).
Effect of chronic fluoxetine on RNA-binding protein AU-rich element/poly(U)-binding/degradation factor-1 in rat frontal cortex We examined whether chronic fluoxetine affected the level of the AU-rich element/poly(U)-binding/degradation factor-1 (AUF-1) RNA-stabilizing protein in nuclear extracts from frontal cortex. 41 The (37 kDa) AUF-1 RNA-binding protein was significantly elevated (59%) in the frontal cortex after chronic fluoxetine (F ¼ 17.25; df ¼ 2, 21; P ¼ 0.0001) but not after chronic fluoxetine with 3-day washout compared to the control level ( Figure 4 ).
Discussion
Chronic (21 days) fluoxetine administration to rats significantly increased activity, protein and mRNA levels of cPLA 2 in rat frontal cortex. However, these significant increases were not observed after a 3-day washout period or with a single acute injection of fluoxetine. The lack of increased cPLA 2 expression after the 3-day saline washout is consistent with a reported half-life of cPLA 2 mRNA of 3-4 h, 52 and known half-lives of fluoxetine and its active metabolite in the blood and brain. (e) Phospholipase A 2 mRNA level in the frontal cortex from rats chronically administered saline (control, n ¼ 6), fluoxetine (n ¼ 6) or fluoxetine with a 3-day washout (washout, n ¼ 6) (*P ¼ 0.010) was measured using real time reverse transcription-polymerase chain reaction (RT-PCR). Each sample was assayed in triplicate in three independent experiments. Data are expressed as the relative level of cPLA 2 in the fluoxetinetreated animals normalized to the endogenous control (b-globulin) and relative to the control rats (calibrator), using the DDC T method. All the data were compared using one-way analysis of variance with Dunnett's post hoc test for multiple comparisons (mean7s.e.m.). Figure 2 Representative immunoblots of calcium independent phospholipase A 2 (iPLA 2 ) (a) (control, n ¼ 8, chronic fluoxetine, n ¼ 8, and chronic fluoxetine followed by a 3-day saline washout, n ¼ 8) and secretory phospholipase A 2 (sPLA 2 ) (b) (control, n ¼ 5, chronic fluoxetine, n ¼ 8, chronic fluoxetine followed by a 3-day saline washout (washout), n ¼ 5) protein levels in the frontal cortex from rats chronically administered saline, fluoxetine and fluoxetine with 3-day washout. Data are ratios of optical density of iPLA 2 or sPLA 2 to b-actin, expressed as the percent of control, and compared using one-way analysis of variance with Dunnett's post hoc test for multiple comparisons (mean7s.e.m.).
The increased cPLA 2 activity after chronic fluoxetine was likely owing to an increased protein level and increased phosphorylation of cPLA 2 . Earlier studies have shown that phosphorylation at serine 505 of cPLA 2 protein by mitogenactivated protein kinase (MAPK p38) resulted in cPLA 2 activation. 53, 54 Another study reported that fluoxetine activates MAPK p38 activity in cultured rat astrocytes, 55 which could account for the increased phosphorylation of cPLA 2 by chronic fluoxetine. The difference in the percent increase of cPLA 2 protein level (54%) compared to the percent increase in phosphorylated cPLA 2 (serine 505) level (27%) may represent differences in MAPK activity 54 and cPLA 2 protein half-life. The difference in the percent increase of cPLA 2 activity (38%) compared to its phosphorylation may be owing to other kinases (protein kinase C (PKC) or MAPK p42) that phosphorylate cPLA 2 at other sites, 56, 57 or it may reflect methodological differences. Increased expression was specific for cPLA 2 as sPLA 2 and iPLA 2 protein levels were not changed significantly after chronic fluoxetine. Cytosolic phospholipase A 2 protein levels were likely increased because of the increased level of mRNA. Consistent with this neither, cPLA 2 mRNA nor protein was increased in the frontal cortex of animals chronically administered fluoxetine followed by a 3-day washout.
Chronic fluoxetine did not significantly alter any of five measured cPLA 2 regulating transcription factors (AP-1, AP-2, GRE, NF-kB and PEA3). This suggests that the increased mRNA was owing to post-transcriptional changes as opposed to a transcription change. Several known factors can enhance the half-life of cPLA 2 mRNA in vitro. Epidermal growth factor, platelet derived growth factor, phorbol 12-myristate 13-acetate and cytokines increase steady-state cPLA 2 mRNA in cultured rat glomerular mesangial cells. 52 An increase in cPLA 2 mRNA could result from either increased transcription or decreased degradation. 52 There FLU-WASHOUT * * * Figure 4 Representative immunoblots of nuclear AU-rich element/ poly(U)-binding/degradation factor (AUF-1) protein levels in the frontal cortex from rats chronically administered saline (control, n ¼ 8), fluoxetine (n ¼ 8) or fluoxetine with 3-day washout (n ¼ 8). Data are ratios of optical density of AUF-1 to b-actin, expressed as the percent of control, and compared using an unpaired t-test (mean7s.e.m., ***P ¼ 0.0001).
are three ATTTA motifs distributed over a 180 bp region in the 3 0 untranslated region, and cPLA 2 mRNA can be destabilized by the presence of inserted adenosine-uridinerich element. 52 The attachment of RNA-binding protein to mRNA can stabilize mRNA and decrease its degradation, thus increasing its half-life. Thus, the increase in nuclear 37 kDa AUF-1 protein in rat frontal cortex after chronic fluoxetine but not after fluoxetine plus washout could have accounted for the increased cPLA 2 mRNA, which would further contribute to the increased expression and activity of cPLA 2 .
Chronic fluoxetine is reported to increase phospholipase C (PLC) activity 11 and 5-HT 2A receptor density in the postmortem brain of patients with depression. 13 This implies that chronic fluoxetine can enhance 5-HT 2 -coupled activation of PLC and possibly other 5-HT receptor-coupled effectors such as PLA 2 . Like fluoxetine, the SSRI fluvoxamine increased rat cortex total PLA 2 activity after 7 days but not after 1 day of administration. 58 Chronic fluoxetine's ability to increase cPLA 2 activity could increase the turnover of arachidonic acid in brain phospholipids. Acute fluoxetine administration to awake rats increases arachidonic acid incorporation into phospholipids at 5-HT 2A/2C containing sites of brain, 33 and chronic fluoxetine could have a similar effect. This is supported by the recent evidence that even chronic fluoxetine followed by a 3-day washout increased the incorporation coefficients of arachidonic acid in the brain of unanesthetized rats. 59 Several studies report that chronic administration of drugs (lithium, valproic acid and carbamazepine) effective in the manic phase of bipolar disorder selectively decrease the turnover of arachidonic acid in brain phospholipids of unanesthetized rats. [34] [35] [36] 60, 61 Although valproate likely targets a long-chain acyl-Coenzyme A synthetase, 62 lithium and carbamazepine decrease the mRNA, protein and activity levels of cPLA 2 , 37,38 most likely by decreasing the AP-2 transcription factor. 47,48 sPLA 2 and iPLA 2 expression are unaffected by chronic lithium or carbamazepine. 37, 63 Monotherapy with SSRIs in patients with bipolar depression often induces switching to mania. 2, 40 Thus, it is possible that drugs effective in depression have opposite effects on the arachidonic acid cascade, particularly on cPLA 2 , compared to the effects of drugs effective in mania, which implies that activity of the arachidonic acid cascade may correlate with mania or depression in bipolar disorder. Testing other SSRIs and antidepressants may help to confirm this hypothesis.
Increased arachidonic acid signaling can modulate PKC 64 and the neuroendocrine system. Arachidonic acid regulates the release of adrenal corticotrophin hormone from cultured anterior pituitary cells 65 and corticotrophin-releasing factor 66 from superfused rat hypothalami. The hypothalamic-pituitary-adrenal (HPA) axis is altered in patients with depression, who have a reduced plasma cortisol response to dexamethasone/corticotrophin. 67 Thus, increasing arachidonic acid signaling could have beneficial effects in depression by upregulating the HPA axis. More studies are needed to elucidate the relations between SSRIs, arachidonic acid metabolism and neuroendrocrine function.
In conclusion, 21 days of fluoxetine administration to adult rats at a therapeutically relevant dose increased the mRNA, protein, phosphorylation and activity levels of cPLA 2 in the frontal cortex, without altering sPLA 2 or iPLA 2 protein levels. These effects may lead to an upregulation of the brain arachidonic acid cascade, which remains to be tested. They did not occur with acute fluoxetine administration and disappear after 3-days of washout. As chronic fluoxetine increases cPLA 2 activity, whereas several drugs effective in treating mania decrease cPLA 2 activity, it may be that the arachidonic acid cascade is increased in mania and decreased in bipolar depression. This could be tested in humans using positron emission tomography. 68, 69 Further studies examining a broad class of antidepressants on the regulation of the arachidonic acid cascade are warranted.
Materials and methods
Animals
The study was conducted following the National Institutes of Health Guidelines for the Care and Use of Laboratory Animals (Publication no. 80-23), and was approved by the Animal Care and Use Committee of the National Institute of Child Health and Human Development. Male CDF-344 rats, weighing 200-215 g (Charles River Laboratories; Wilmington, MA, USA), were acclimatized for 1 week in an animal facility with controlled temperature, humidity and light cycles and food and water were provided ad libitum.
Rats were randomly assigned into three chronic treatment groups and administered drug or saline by i.p. injection. First group (control, n ¼ 8) received vehicle (0.9% saline) once daily for 21 days, a second group (fluoxetine, n ¼ 8) received 10 mg/kg fluoxetine (Prozac; (7)-N-methyl-g-[4-(trifluoromethyl) phenoxy] benzenepropanamine; Sigma Chemical Co., St Louis, MO, USA) once daily for 21 days, and a third group (washout, n ¼ 8) received the same 21-day drug regimen as the fluoxetine group but followed by a 3-day drug-free period in which the rats received vehicle injections. This chronic dosing regimen of fluoxetine has been shown to decrease depression in rodents as measured by a variety of behavioral tests and biomarkers related to depression. [70] [71] [72] Three hours after the last drug or saline injection, all rats were anesthetized with CO 2 and decapitated. The brain was rapidly excised and the frontal cortex dissected, frozen in 2-methylbutane at À501C and stored at À801C until use.
For acute fluoxetine studies, animals were randomized into two treatment groups that received a single intraperitoneal (i.p.) injection of either 10 mg/kg fluoxetine (n ¼ 8) (Sigma Chemical Co., St Louis, MO, USA), or an equivalent volume of saline (vehicle) (n ¼ 8). Three hours after injection, animals were anesthetized with CO 2 and decapitated, and the frontal cortex was removed and stored as described above.
Preparation of cytoplasmic and nuclear extracts Cytoplasmic and nuclear extracts were prepared from the frontal cortex of rats, as described previously. 48 Protein concentrations of cytoplasmic and nuclear extracts were determined using Bio-Rad protein Reagent (Bio-Rad, Hercules, CA, USA).
Western blot analysis
Proteins from cytoplasmic and nuclear extract (75 mg) were separated on 10-20% SDS-polyacrylamide gels (PAGE) (Bio-Rad). Following SDS-PAGE, the proteins were electrophoretically transferred to a nitrocellulose membrane. Cytoplasmic protein blots were incubated overnight in Tris-buffered saline buffer, containing 5% non-fat dried milk and 0.1% Tween-20, with specific primary antibodies (1:200 dilution) for the group IVA cPLA 2, group IIA sPLA 2 , group VIA iPLA 2 73 (Santa Cruz Biotech, Santa Cruz, CA, USA) and phosphocPLA 2 (1:500 dilution) (Cell Signaling, Beverly, MA, USA). The nuclear AUF-1 protein levels were determined using nuclear protein blots incubated overnight with specific primary antibody (1:200 dilution) for AUF-1 (Upstate USA Inc., Charlottesville, VA, USA). Cytoplasmic and nuclear protein blots were incubated with appropriate horse radish perxidase (HRP)-conjugated secondary antibodies (Bio-Rad) and visualized using a chemiluminescence reaction (Amersham, Piscataway, NJ, USA) on X-ray film (XAR-5, Kodak). Optical densities of immunoblot bands were measured using Alpha Innotech Software (Alpha Innotech, San Leandro, CA, USA) and were normalized to b-actin (Sigma) to correct for unequal loading. All experiments were carried out twice with eight independent samples. Values are expressed as the percent of control.
Total RNA isolation and real-time reverse transcription-Polymerase chain reaction Total RNA and cDNA were prepared as described 48 from frontal cortex and measured by real-time quantitative reverse trancription-Polymerase chain reaction (RT-PCR), using the ABI PRISM 7000 sequence detection system (Applied Biosystems, Foster City). Specific primers and probes for cPLA 2 , purchased from TaqMan R gene expression assays (Applied Biosystems), consisted of a 20 Â mix of unlabeled PCR primers and Taqman minor groove binder (MGB) probe (FAM dye-labeled). The fold change in gene expression was determined using the DDC T method. 74 Data were expressed as the relative level of the target gene (cPLA 2 ) in the chronic fluoxetine, chronic fluoxetine with washout and acute fluoxetine animals normalized to the endogenous control (b-globulin) and relative to the control rats (saline injected) (calibrator), as described previously. 37, 48 All experiments were carried out twice in triplicate with six independent samples per group.
Phospholipase A 2 activity Frontal cortex cPLA 2 activity was measured as described by Yang et al. 18 Briefly, a portion of the cytoplasmic fraction was incubated in 100 mM 1-palmitoyl-2-arachidonoyl-snglycerol-3-phosphorylcholine and phosphatidylinositol 4,5-bisphosphate (97:3) containing approximately 100 000 c.p.m. of 1-palmitoyl-2-[1-
14 C] arachidonoyl-sn-glycerol-3-phosphorylcholine and 4,5 biphosphatidylinositol in 400 mM Triton X-100 mixed micelles containing 100 mM Hepes, pH 7.5, 80 mM Ca 2 þ , 2 mM dithiothretiol (DTT) and 0.1 mg/ml fatty acid-free bovine serum albumin. The assay was started by adding the reagent to cytoplasmic extracts for 30 min at 401C in a shaking bath. The reaction was terminated by the addition of Dole's reagent (2-propanol: heptane:0.5 M sulfuric acid, 400:100:20, by volume) followed by vortexing. Released [1- 14 C]arachidonic acid was extracted with the addition of heptane and water. One milliliter of the heptane was loaded on a bond elute reservoir with a frit preloaded with silicic acid. The free [1- 14 C]arachidonic acid was eluted from the silicic acid and by adding diethyl ether with the help of a vacuum. Radioactivity of the elutant was then determined by liquid scintillation counting, and activity was calculated after correcting for the background of blank samples. All samples were run in triplicate and values were expressed in pmol/ min/mg of protein.
Electrophoretic mobility shift assay Gelshift assays were performed on the nuclear extracts from rat frontal cortex to examine the DNA-binding activities of transcription factors (AP-1, AP-2, GRE, NF-kB, PEA3) known to regulate cPLA 2 mRNA expression. Nuclear protein extracts (15 mg) were incubated with a non-radioactive (10 ng) biotin-labeled DNA oligo consensus (Panomics, Redwood City, CA, USA) in gelshift buffer (10 mM Tris-HCl, pH 7.5, 1 mM NaCl, 1 mM MgCl 2 , 0.5 mM ethylenechiamine tetraacetic acid , 0.5 mM DTT, 4% glycerol and 50 mg/ml poly-dI:dC) for 30 min on ice. The DNA-protein complex was separated on a 5% Tris-borate EDTA (TBE) gel and electrophoretically transferred to a nylon membrane. The biotin-labeled oligonucleotide complex was visualized using a streptavidin-HRP conjugate coupled with chemiluminescence on X-ray film (Kodak, Rochester, NY, USA). The following oligonucleotide sequences were used for the gelshift assay: AP-1 -CGCTTGATGAGTCAGCCGGAA; NFkB -AGTTGAGGGGACTTTC C CGGC; AP-2 -GATCGAACT GACCGCCCGCGGCCCGT; GRE -GACCCTAGAGGATCTG TACAG GATGTTCTAGATCCAATTCG and PEA3 -GATCTCG AGCAGGAAGTTA. The specificity of each transcription factor was determined using 100 times excess unlabeled probe with a fixed amount of biotin-labeled DNA oligo consensus (10 ng) and nuclear extracts (15 mg). Optical densities of gelshift bands were quantified using Alpha Innotech software (Alpha Innotech). Values were expressed as the percent of control.
Statistical analysis
Data are expressed as mean7s.e.m. When three groups were compared (chronic fluoxetine, chronic fluoxetine with washout and control), statistical significance was determined using a one-way analysis of variance with Dunnett's post hoc test for multiple comparisons vs control. Statistical significance was set at Pp0.05. When two groups were compared (acute fluoxetine and control), statistical significance was determined using an unpaired two-tailed t-test. 
